Drug Search Results
Using advanced filters...
Advanced Search [+]

Lacripep

Alternative Names: lacripep
Latest Update: 2025-03-03
Latest Update Note: Clinical Trial Update

Product Description

Lacripep, which is derived from the Lacritin protein, is a first-in-class topical therapy that preserves all of Lacritin’s bioactivity. (Sourced from: https://tearsolutions.com)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: TearSolutions
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Corneal Injuries

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

WRNMMC-2024-0470

P2

Not yet recruiting

Corneal Injuries

2027-06-01

Recent News Events